(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

7, 2025 – A new light therapy device could be a game-changer for millions at risk of vision loss. The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...

It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...

Dry macular degeneration is a common eye disorder among people aged above 50 years ... Eyevensys and others are evaluating new dry AMD drugs to improve the treatment landscape. Promising dry AMD ...